Evidence map›Paper›PMID 40133704›Full record

ArticleCommunications biology2025

A combined mathematical and experimental approach reveals the drivers of time-of-day drug sensitivity in human cells.

Nica Gutu, Hitoshi Ishikuma, Carolin Ector, Ulrich Keilholz, Hanspeter Herzel, Adrián E Granada

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nica GutuComprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Hitoshi IshikumaComprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.ORCID http://orcid.org/0009-0007-9961-422X
Carolin EctorComprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Ulrich KeilholzComprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Hanspeter HerzelHumboldt Universität zu Berlin, Berlin, Germany.
Adrián E GranadaComprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany. adrian.granada@charite.de.ORCID http://orcid.org/0000-0003-0537-9091

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The circadian clock plays a pivotal role in regulating various aspects of cancer, influencing tumor growth and treatment responses. There are significant changes in drug efficacy and adverse effects when drugs are administered at different times of the day, underscoring the importance of considering the time of day in treatments. Despite these well-established findings, chronotherapy approaches in drug treatment have yet to fully integrate into clinical practice, largely due to the stringent clinical requirements for proving efficacy and safety, alongside the need for deeper mechanistic insights. In this study, we employ a combined mathematical and experimental approach to systematically investigate the factors influencing time-of-day drug sensitivity in human cells. Here we show how circadian and drug properties independently shape time-of-day profiles, providing valuable insights into the temporal dynamics of treatment responses. Understanding how drug efficacy fluctuates throughout the day holds immense potential for the development of personalized treatment strategies aligned with an individual's internal biological clock, revolutionizing cancer treatment by maximizing therapeutic benefits. Moreover, our framework offers a promising avenue for refining future drug screening efforts, paving the way for more effective and targeted therapies across diverse tissue types.

Indexed as

Antineoplastic AgentsCircadian ClocksCircadian RhythmNeoplasmsCell Line, TumorHumansModels, BiologicalAntineoplastic Agents

Identifiers

PMID40133704
PMCPMC11937577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.